Abstract

BackgroundHypocretins/orexins (Hcrt/Ox) are hypothalamic neuropeptides involved in sleep-wakefulness regulation. Deficiency in Hcrt/Ox neurotransmission results in the sleep disorder narcolepsy, which is characterized by an inability to maintain wakefulness. The Hcrt/Ox neurons are maximally active during wakefulness and project widely to the ventral tegmental area (VTA). A dopamine-containing nucleus projecting extensively to the cerebral cortex, the VTA enhances wakefulness. In the present study, we used retrograde tracing from the medial prefrontal cortex (mPFC) to examine whether Hcrt1/OxA neurons target VTA neurons that could sustain behavioral wakefulness through their projections to mPFC.ResultsThe retrograde tracer Fluorogold (FG) was injected into mPFC and, after an optimal survival period, sections through the VTA were processed for dual immunolabeling of anti-FG and either anti-Hcrt1/OxA or anti-TH antisera. Most VTA neurons projecting to the mPFC were located in the parabrachial nucleus of the ipsilateral VTA and were non-dopaminergic. Only axonal profiles showed Hcrt1/OxA-immunoreactivity in VTA. Hcrt1/OxA reactivity was observed in axonal boutons and many unmyelinated axons. The Hcrt1/OxA immunoreactivity was found filling axons but it was also observed in parts of the cytoplasm and dense-core vesicles. Hcrt1/OxA-labeled boutons frequently apposed FG-immunolabeled dendrites. However, Hcrt1/OxA-labeled boutons rarely established synapses, which, when they were established, were mainly asymmetric (excitatory-type), with either FG-labeled or unlabeled dendrites.ConclusionsOur results provide ultrastructural evidence that Hcrt1/OxA neurons may exert a direct synaptic influence on mesocortical neurons that would facilitate arousal and wakefulness. The paucity of synapses, however, suggest that the activity of VTA neurons with cortical projections might also be modulated by Hcrt1/OxA non-synaptic actions. In addition, Hcrt1/OxA could modulate the postsynaptic excitatory responses of VTA neurons with cortical projections to a co-released excitatory transmitter from Hcrt1/OxA axons. Our observation of Hcrt1/OxA targeting of mesocortical neurons supports Hcrt1/OxA wakefulness enhancement in the VTA and could help explain the characteristic hypersomnia present in narcoleptic patients.

Highlights

  • Hypocretins/orexins (Hcrt/Ox) are hypothalamic neuropeptides involved in sleep-wakefulness regulation

  • Much emphasis has been placed on the dopaminergic mesocortical system in previous studies, some reports indicate that GABA-containing ventral tegmental area (VTA) neurons project to the medial prefrontal cortex (mPFC) [6]

  • The retrograde tracer stained all layers of the cerebral cortex; in one animal (R31; prelimbic sector (PL)) the FG deposit was mainly in superficial layers and in another animal (R40; Anterior cingulate cortex (Cg1)-PL) the FG injection was confined to layers I-V (Cg1-PL)

Read more

Summary

Introduction

Hypocretins/orexins (Hcrt/Ox) are hypothalamic neuropeptides involved in sleep-wakefulness regulation. The Hcrt/Ox neurons are maximally active during wakefulness and project widely to the ventral tegmental area (VTA). The ventral tegmental area (VTA) comprises several subdivisions including the paranigral (PN), parabrachial (PBP) or interfascicular (IF) nuclei [1]. Neurons synthesizing neurotransmitters, such as dopamine (DA), GABA or glutamate among others coexist in these VTA divisions [2,3]. The mesocortical system, which is strongly involved in cognitive behavior, EEG activation and arousal, is formed by VTA projections to areas of the cerebral cortex located mainly in the medial surface of the frontal lobe [4]. Systematic studies assessing the relative contributions of dopaminergic and non-dopaminergic neurons to the mesocortical pathway reaching mPFC have not been addressed so far

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call